TAMPA, Fla.--(BUSINESS WIRE)--
Oragenics, Inc. (NYSE MKT:OGEN), a leader in the development of new antibiotics against infectious diseases and developing effective treatments for oral mucositis, today announced a poster presentation at the joint American Society for Microbiology (ASM) General Meeting and Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) held at the New Orleans Ernest N. Morial Convention Center in New Orleans, LA, from June 1-5, 2017.
The poster entitled “Development of OG716, a Novel Lantibiotic Against Clostridium difficile” presented the pivotal IND-enabling in vitro and animal studies that will be used to support the non-clinical characterization of the Company’s lead compound, OG716, as well as inform the design for the first-in-man clinical studies. Also highlighted was Oragenics’ unique library of over 700 proprietary lantibiotic variants, which were developed in collaboration with Intrexon Corporation (NYSE:XON).
Lantibiotics represent a novel class of antibiotics with a unique mechanism of action against multidrug resistant microbes. Several new lantibiotic variants generated from Oragenics’ Mutacin 1140 platform have demonstrated promising efficacy in reducing clinically relevant Clostridium difficile infections as measured by increased animal survival and decreased relapse as well as reduced production of Clostridium difficile spores and toxins in comparison to a vancomycin positive control.
Dr. Alan Joslyn, Chief Executive Officer and President of Oragenics, said, “As we move forward with preparations for an IND filing for our lead compound, OG 716, for treatment of Clostridium difficile, we are continuing to explore our vast library of lantibiotic variants in pre-clinical studies. We believe that we are uniquely positioned to develop a novel class of antibiotics for the treatment of severe unmet medical needs. The current efficacy data generated utilizing lantibiotic variants developed with our partner, Intrexon, further highlights the collaborative advancement of our lantibiotic research.”
Through an Exclusive Channel Collaboration agreement (ECC) with Intrexon, the Company has ongoing research and development activities directed toward the identification of active lantibiotic homologs with the goal of selecting molecules that have favorable efficacy, safety and drug delivery profiles. Once identified, the Company intends to advance top candidates in a timely and cost effective manner to treat a variety of multidrug resistant bacterial infections.
About Oragenics, Inc.
We are focused on becoming the world leader in novel antibiotics against infectious disease and on developing effective treatments for oral mucositis. Oragenics, Inc. has established two exclusive worldwide channel collaborations with Intrexon Corporation, a synthetic biology company. The collaborations allow Oragenics access to Intrexon's proprietary technologies toward the goal of accelerating the development of much needed new antibiotics that can work against resistant strains of bacteria and the development of biotherapeutics for oral mucositis and other diseases and conditions of the oral cavity, throat, and esophagus.
For more information about Oragenics, www.oragenics.com
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect management’s current views with respect to future events and performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, our current need for financing to meet our operational needs and to be able to move our product candidates forward through pre-clinical and clinical development, our inability to obtain sufficient financing to conduct our business; any inability to obtain or delays in the Food and Drug Administration approval for future clinical studies and testing, the future success of our studies and testing and any inability to also achieve favorable results in human studies, our ability to successfully develop and commercialize products, the financial resources available to us to continue research and development, any inability to regain compliance with the NYSE MKT continued listing requirements and those other factors described in our filings with the U.S. Securities and Exchange Commission. Any responsibility to update forward-looking statements is expressly disclaimed.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170606006721/en/
